Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in
patients with CD30-positive cancers. The study will assess electrical activity of the heart
before and after brentuximab vedotin administration. Patients who have stable or improving
disease may receive up to 1 year of brentuximab vedotin treatment.